Aptose Biosciences Inc To Hold Clinical Update Call Transcript
Good afternoon. I would like to welcome everyone to the Aptose Biosciences' clinical update and data review in conjunction with the European School of Hematology, ESH 6th International Conference. (Operator Instructions) After the speakers' remarks, there will be a question-and-answer session.
Joining me on today's call are Dr. William Rice, Chairman and CEO; Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer; and our special guest and key opinion leader, Dr. Naval Daver from the MD Anderson Cancer Center.
I will now turn the call over to Dr. Rice, Chairman and CEO of Aptose Biosciences. Please go ahead.
Thank you. Good morning, all. Today, we'll come to you from the European School of Haematology Conference being held in Estoril, Portugal. It's my pleasure to welcome you to our clinical update and KOL data review for Aptose's lead agent Tuspetinib that's being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia or AML. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |